The incremental share increase is routine portfolio rebalancing by a large passive manager. No change in investment thesis; monitor next 13F for broader institutional positioning trends.
VRTX drugs
VRTX drug pipeline →- ▲ povetacicept 6/10 Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p · PDUFA date Nov 30, 2026
- ● inaxaplin 5/10 Phase 2/3
- ▲ ALYFTREK 4/10 Approved
- ● JOURNAVX 4/10 Approved
- ● TRIKAFTA 4/10 Approved
- 6 more · All VRTX drugs, catalysts & trials →
Price Chart
How similar events traded
Executive Summary
Capital Research Global Investors filed an amended Schedule 13G disclosing a 7.0% passive stake in Vertex Pharmaceuticals as of September 30, 2026, representing 17,821,661 shares. This is an increase from the prior filing (May 2026) which showed 17,794,137 shares, a net addition of approximately 27,524 shares. The filing confirms CRGI remains a passive investor with no control intent.
Key Financial Metrics
Key Facts
- Capital Research Global Investors holds 17,821,661 shares of Vertex common stock as of September 30, 2026
- Stake represents 7.0% of 253,460,924 shares outstanding
- This is an amendment to Schedule 13G, indicating passive investment intent
- Prior filing (May 2026) showed 17,794,137 shares; net increase of ~27,524 shares
Financial Impact
Stake valued at approximately $9.7B based on $138.7B market cap and 7.0% ownership
Risk Factors
- Passive 13G filers may convert to 13D if they become activist, though no indication here
- Large institutional ownership concentration (Capital Group entities combined hold significant stake) could amplify selling pressure if they reduce
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001422848-26-000142 |
| Document: 0001422848-26-000142-index.html | 0001422848-26-000142 |
| Document: 0001422848-26-000142.txt | 0001422848-26-000142 |
Track record
21 reports on VRTX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Viewing Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers